Annovis Bio Launches Proposed Public Offering of Common Stock and Warrants

PUBT · 14h ago
Annovis Bio Launches Proposed Public Offering of Common Stock and Warrants
  • Annovis Bio launched a proposed underwritten public offering of common stock or pre-funded warrants, with accompanying warrants to purchase common stock.
  • The common stock or pre-funded warrants and accompanying warrants will be issued separately but must be purchased together.
  • Net proceeds will fund buntanetap clinical development for Alzheimer's and Parkinson's diseases, working capital and general corporate purposes.
  • Canaccord Genuity is the sole bookrunner.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041607PRIMZONEFULLFEED9870573) on November 04, 2026, and is solely responsible for the information contained therein.